Hemay808
DrugHemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
NCT Number: NCT04352595
Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Dermotology hospital, Chinese academy of medical science, Nanjing, Jiangsu, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
Time frame: Day 29
EASI Clinical Signs Severity Sum Score change from Baseline at Day 29
Time frame: Day 8, Day 15, Day 22, Day 28
The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Time frame: Day 8, Day 15, Day 22, Day 28
The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Time frame: Day 8, Day 15, Day 22, Day 28
Change From Baseline in the IGA Clinical Signs Severity Sum Score.
Time frame: Day 8, Day 15, Day 22, Day 28
EASI Clinical Signs Severity Sum Score ≥50%, 75%, 90% improvement from baseline.
Time frame: Day 8, Day 15, Day 22, Day 28
Range of 0 (No itch) to 10 (Worst imaginable itch)
Time frame: Day 8, Day 15, Day 22, Day 28
The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality
Time frame: Day 8, Day 15, Day 22, Day 28
AD invoved body surface area.
Tianjin Hemay Pharmaceutical Co., Ltd
Industry
Assess Hemay808 Concentration of Different Dosage Regimen for Mild and Moderate Atopic Dermatitis Patients the Safety and Efficacy of Multicenter, Randomized, Blinded, Excipient Parallel-group Phase Ⅱ Clinical Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06687512
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ahmedabad, Gujarat, India
View Trial DetailsNCT05613062
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsNCT05633355
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT05899816
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Scottsdale, Arizona, United States
View Trial Details